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Purpose. Ifosfamide is a drug commonly used in the management of sarcomas and other solid tumours. One potential toxicity of
its use is renal tubular damage, which can lead to skeletal abnormalities; rickets in children and osteomalacia in adults. We aimed
to characterise this rare complication in adults. Patients. Three illustrative patient cases treated in our institution are presented.
All were treated for sarcoma, and received varying doses of ifosfamide during their therapy. Methods. We performed a review of
the literature on the renal tubular and skeletal complications of ifosfamide in adults. Papers were identiﬁed by searches of PubMed
using the terms “osteomalacia,” “nephrotoxicity,” “Fanconi syndrome,” “ifosfamide,” and “chemotherapy” for articles published
between1970and2006.Additionalpaperswereidentiﬁedfromreviewofreferencesofrelevantarticles.Results.Thereareonlyfour
casereportsofskeletaltoxicitysecondarytoifosfamideinadults;themajorityofdatarefertochildren.Riskfactorsfordevelopment
of renal tubular dysfunction and osteodystrophy include platinum chemotherapy, increasing cumulative ifosfamide dose, and
reduced nephron mass. The natural history of ifosfamide-induced renal damage is variable, dysfunction may not become apparent
until some months after treatment, and may improve or worsen with time. Discussion. Ifosfamide-induced osteomalacia is seldom
described in adults. Clinicians should be vigilant for its development, as timely intervention may minimise complications.
Copyright © 2007 D. N. Church et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Ifosfamide is an alkylating oxazaphosphorine active against a
number of malignancies including bone and soft tissue sar-
comas as a single agent [1, 2] or in combination [3]. The
development of mesna in 1979 largely ameliorated haemor-
rhagic cystitis as a complication of its use [4, 5] and the prin-
cipal associated toxicities became myelosuppression, neuro-
toxicity, and nephrotoxicity; including glomerular, proximal,
and distal tubular dysfunction [6, 7]. If severe, proximal
tubular dysfunction may lead to Fanconi syndrome; char-
acterised by glycosuria, aminoaciduria, and excess urinary
excretion of phosphate, calcium, bicarbonate, potassium,
sodium, and magnesium [8]. Left untreated, hypophos-
phatemia results in skeletal abnormalities: rickets in children
and osteomalacia in adults [8]. While the renal and skeletal
consequences of ifosfamide have been well described in the
paediatric population [6, 7], there is limited information on
such eﬀects in adults.
Here, we report three adult patients in whom osteomala-
cia as a late consequence of ifosfamide-induced renal tubular
dysfunction mimicked skeletal metastases. These cases were
diagnosed over a three-year period at a regional cancer cen-
tre in which approximately 30–40 patients per year receive
ifosfamide-basedchemotherapyforsarcoma.Ineachcaseos-
teomalacia was diagnosed on the basis of radiological ﬁnd-
ings in combination with serum biochemical abnormalities.
WedeﬁneFanconisyndromeasanacquiredrenaltubularde-
fect resulting in excess loss of glucose, bicarbonate, amino
acids, uric acid, and phosphate. All patients described gave
informed consent for publication.
2. METHODS
Literature review was performed by searches of PubMed
using the terms “osteomalacia,” “nephrotoxicity,” “Fanconi
syndrome,” “ifosfamide,” and “chemotherapy” for articles2 Sarcoma
published between 1970 and 2006. Additional papers were
identiﬁed from the references of relevant articles.
3. PATIENTS
3.1. Case1
A 25-year-old man was referred to our institution with an
undiﬀerentiated high-grade soft tissue sarcoma of the right
thigh in March 1998. He had no history of renal disease and
serum electrolytes and creatinine 91µmol/L were normal at
presentation. He received neoadjuvant chemotherapy as de-
scribedinTable 1 (Case1,Regimen1),withoutcomplication
and with normal serum biochemistry throughout. The tu-
mour responded to treatment and the patient proceeded to
radiotherapy (kidneys not included in treatment ﬁeld) and
surgery.
InJanuary2000,lungmetastasesweredetectedinfollow-
up imaging and subsequently resected. No further systemic
therapy was given. However, in August 2000 unresectable
disease progression necessitated palliative chemotherapy
(Table 1, Regimen 2). Biochemistry remained within normal
range during treatment, and a partial response with eﬀective
palliation was achieved.
In June 2001, the patient developed further sympto-
matic progression of disease. Serum creatinine measured
123µmol/L, corresponding to a calculated glomerular ﬁltra-
tion rate (GFR) of 80ml/min according to the method of
Cockroft and Gault [9]. Further chemotherapy was given
(Table 1), but discontinued after 4 cycles due to lack of re-
sponse. In view of the limited treatment options available
and their previous eﬃcacy, single-agent ifosfamide was used
(Table 1). The patient required hospitalization after the ﬁrst
cycle for management of febrile neutropenia with antibiotics
including gentamicin(4doses at4mg/kgdailydose).During
this admission transient hypokalemia (nadir 2.6mmol/L)
and elevation of serum creatinine (maximum 134µmol/L)
were observed. Both normalised with supplementation and
rehydration and remained within normal range during sub-
sequentcourses.Treatmentresultedinsigniﬁcanttumourre-
gression and eﬀective palliation.
In April 2002, ﬁve months after cessation of ifosfamide
treatment, concomitant with further progression of pul-
monary disease, the patient complained of bilateral ankle
pain following a snowboarding holiday. Isotope bone scan
demonstrated increased uptake at sites of symptoms and
serum alkaline phosphatase measured 266IU/L. Though the
possibility of skeletal metastases was considered, careful re-
view of plain radiographs revealed insuﬃciency fractures
of both ankles, conﬁrmed on magnetic resonance (MR)
scan (Figure 1). Biochemistry conﬁrmed the characteristic
hypokalaemia and hypophosphataemia (0.8mmol/L) of re-
nal Fanconi syndrome. There was no urinary sediment and
serum whole parathyroid hormone (PTH) was normal. Oral
alfacalcidolandpotassiumsupplementationwereprescribed.
Unfortunately, over the following months a steady de-
cline in glomerular function developed with haemodialysis
initiated in February 2003. During this period, continued
disease progression occurred and despite treatment with two
(a)
(b)
Figure 1: Case 1: T1-weighted magnetic resonance (MR) demon-
strating stress fractures of (a) right talus and (b) left calcaneum.
nonnephrotoxic regimens (etoposide and gemcitabine) the
patient died from disseminated
malignancy in August 2003.
3.2. Case2
A 33-year-old woman with Ewing’s sarcoma of the left tibia
was referred for management in May 2002. She had no his-
tory of renal disease, and serum creatinine at presentation
measured 98µmol/L. Initial isotope bone scan is shown in
Figure 2(a).
Neoadjuvant chemotherapy was administered, using the
VIDE regimen [10]( Table 1). After the ﬁfth cycle, the pa-
tient was hospitalised for management of febrile neutrope-
nia, including 6 doses of gentamicin at 4mg/kg daily dose
(levels within normal range throughout). During this admis-
sion transient hypokalemia (nadir 3.1mmol/L) and modest
elevationofserumcreatinine115µmmol/Loccurred,though
both normalised with supplementation and rehydration. In
view of this toxicity, the sixth cycle was prescribed at reduced
dose, but further hypokalaemia (nadir 2.7mmol/L) neces-
sitated transient oral supplementation. After completion of
chemotherapy, the patient underwent tumour excision with
a free ﬁbula graft.
Following surgery, adjuvant therapy was commenced in
December 2002 as per standard practice in our institution.
OnecycleofVAI[10](Table 1)wasgiven,butcomplicatedby
febrile neutropenia requiring hospitalization for treatment
including 3 doses of gentamicin at 4mg/kg. During this ad-
mission an asymptomatic rise in creatinine to 167µmol/LD. N. Church et al. 3
Table 1: Chemotherapeutic regimens used in cases. Cis: cisplatin, dox: doxorubicin, ifos: ifosfamide, epi: epirubicin, vinb: vinblstine, dac:
dacarbazine, vinc: vincristine, etop: etoposide, act: actinomycin D, cyclo: cyclophosphamide. Note that cisplatin was administered with pre-
and posthydration and ifosfamide was demonstrated as an infusion with concurrent mesna in all regimens.
Regimen 1 Regimen 2 Regimen 3 Regimen 4 Total ifos dose
Apr–Jul 1998 Aug–Nov 2000 Jun–Aug 2001 Oct-Nov 2001
Case 1
Cis 100mg/m2,d 1
Dox 25mg/m2,d 1 – 3
Alternating with
Ifos 5g/m2,d 1
Dox 25mg/m2,d 1 – 3
5c y c l e st o t a l
Ifos 3.33g/m2,d 1 – 4
5c y c l e s( #1 at reduced
dose)
Epi 90mg/m2,d 1
Cis 75mg/m2,d 1
Alternating with
Vinb 5mg/m2,d 1
Cis 75mg/m2,d 1
Dac 800mg/m2,d 1
4c y c l e st o t a l
Ifos 3.33g/m2,d 1 – 4
3c y c l e s
Total ifos 10g/m2 60g/m2 40g/m2 110g/m2
Jun–Oct 2002 Dec 2002–Feb 2003
Case 2
Vinc 1.4mg/m2,d 1
Ifos 3g/m2,d 1 – 3
Dox 20mg/m2,d 1 – 3
Etop 150mg/m2,d 1 – 3 10
6c y c l e s( #6a t6 5 % dose)
Vinc 1mg/m2,d 1
Act 0.75mg/m2,d 1 ,2
Ifos 3g/m2 d1, 2
3 cycles, cyclo-sub-
stituted for ifos after #1
——
Total ifos 51g/m2 6g/m 2 —— 5 7 g / m 2
Jun–Sept 2004
Case 3
VIDE (as above)10
4c y c l e s( r e d u c e dd o s ei f o s
from #3)
———
Total ifos 24g/m2 ——— 2 4 g / m 2
occurred. Cyclophosphamide was therefore substituted for
ifosfamide for subsequent courses, which were well tolerated
with biochemistry remaining within normal range through-
out.
Six months after completion of therapy and 10 months
after surgery, the patient still complained of signiﬁcant
pain at the operation site. Plain radiographs demonstrated
nonunion of the ﬁbula graft but also areas of lucency in
the proximal and distal tibia are demonstrated. Isotope bone
scan added to suspicion of metastases, with several areas
of increased uptake evident (Figure 2(b)). MR performed
to further delineate the abnormality revealed a stress frac-
ture within the ﬁbula graft, and biopsies conﬁrmed heal-
ing tissue only with no evidence of malignancy. Serum bio-
chemistry demonstrated hypokalaemia and elevated alkaline
phosphatase, conﬁrming the diagnosis of osteomalacia sec-
ondarytoFanconisyndrome.Nourinarysedimentwasiden-
tiﬁed, serum whole PTH was normal throughout. Oral alfa-
calcidol supplementation was commenced.
As of May 2006, the patient is clinically well under joint
oncology and nephrology followup with no evidence of re-
current malignancy. She continues to require vitamin D sup-
plementation and serum creatinine remains elevated, but
stable at 133µmol/L.
3.3. Case3
A 31-year-old man was referred in May 2004 for further
management of a peripheral neuroectodermal tumour of the
left kidney, having undergone left nephrectomy the preced-
ingmonth.Hehadnohistoryofrenaldiseaseandserumcre-
atinine at presentation measured 81µmol/L.
Staging investigations demonstrated no evidence of me-
tastases and he therefore received adjuvant therapy using
the VIDE regimen [10]( Table 1). Following the second cy-
cle of treatment, the patient required hospitalization for
management of nausea and vomiting. Signiﬁcant biochem-
ical derangement was noted on admission; serum creati-
nine measured 224µmol/L; urea 11.1mmol/L; potassium
2.9mmol/L; phosphate <0.3mmol/L, and corrected calcium
2.06mmol/L. Electrolytes normalised with supplementation
and serum creatinine fell to 129µmol/L prior to cycle 3, for
which a reduced dose of ifosfamide was used. Despite this,
the patient again required hospital admission for manage-
ment of febrile neutropenia after the two subsequent cy-
cles, on both occasions treated without aminoglycosides.
Although serum potassium remained within normal range
during this period without supplementation, following the
fourth and ﬁnal cycle marked hypophosphatemia (nadir
<0.3mmol/L) and elevation of serum creatinine 162µmol/L
were noted. Treatment was completed in September 2004.
During initial followup serum creatinine remained ele-
vated but stable at 143–157µmol/L and the patient was able
to discontinue all electrolyte supplementations. However in
November 2004 a progressive decline in glomerular function
became evident, with increase in creatinine to 300µmol/L.
Toexcludeobstructiveuropathysecondarytoretroperitoneal
tumour recurrence as cause of this, a CT of the abdomen and
pelvis was performed. While this demonstrated no evidence
of outﬂow obstruction, it revealed a number of abnormal4 Sarcoma
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Figure 2: Case 2: isotope bone scans, (a) at diagnosis, demonstrating increased uptake at site of primary tumor in left tibia, (b) after
ifosfamide therapy and surgery, demonstrating continued increased uptake at site of primary tumor and new abnormality in region of right
ankle.
areas throughout the skeleton. A bone scan to further assess
these showed increased uptake in the region of the left an-
kle. Further biochemical analysis conﬁrmed elevated alkaline
phosphatase, hypocalcaemia, and hypophosphataemia; con-
sistent with osteomalacia secondary to Fanconi syndrome.
Whole PTH was normal with no urinary sediment. Oral al-
facalcidol supplementation was commenced.
Unfortunately, glomerular function continued to decline
oversubsequentmonths,renalbiopsyrevealedmarkedinter-
stitial ﬁbrosis, with dialysis initiated in August 2005. At time
of this report (May2006), the patient is free fromrecurrence,
under joint oncology and nephrology followup.
4. DISCUSSION
The three cases presented illustrate the potential for the de-
layed development of osteomalacia secondary to ifosfamide-
induced Fanconi syndrome in adult patients. Cumulative
drug doses were variable; 110g/m2,5 7g / m 2,a n d2 4g / m 2 in
Cases1,2,and3,respectively.Inadditiontotubulardysfunc-
tion, each patient has shown evidence of associated deranged
glomerular ﬁltration, with two patients requiring dialysis.
Ifosfamide is associated with a variety of renal toxici-
ties (see Skinner [6, 7] for comprehensive reviews)including
glomerular dysfunction leading to fall in glomerular ﬁltra-
tion rate (GFR) [11–15], distal tubular damage leading to
poor urinary concentrating ability [16, 17], and more com-
monly, proximal tubular dysfunction [7, 13, 15] thought
to be caused by chloroacetaldehyde [18–20], a metabo-
lite of ifosfamide toxic to human proximal tubular cells
[21]. Although mesna is theoretically capable of detoxifying
chloroacetaldehyde, its eﬃcacy may be incomplete [22]a n d
its rapid tubular excretion may further impair any protective
action at this site.
The incidence of proximal tubular dysfunction in chil-
dren treated with ifosfamide varies according to the crite-
ria used for assessment. While subclinical glycosuria was de-
tected in 88% of patients in a large study [14], clinically sig-
niﬁcant abnormalities including Fanconi syndrome occur in
between 1.3 and 27% of treated patients [11, 17, 23, 24]. Risk
is increased by prior or concurrent platinum chemother-
apy [11, 13, 15, 25, 26], increasing cumulative ifosfamide
dose [12–14, 17, 25, 27], and reduced functioning nephron
mass [13, 23, 25, 28], but not scheduling of ifosfamide dose
[29, 30]. Whether aminoglycoside use increases risk is un-
clear [14, 31] although aminoglycosides per se may cause
Fanconi syndrome [32].
It is important to note that whilst tubular damage sec-
ondary to ifosfamide may become apparent during therapy,
it can develop months or even years after cessation of treat-
ment [33, 34] as in these cases. The subsequent natural his-
tory is equally unpredictable; though damage may resolve
with time [6, 33], with spontaneous resolution of secondary
rickets [35], there may be no improvement in tubular func-
tion [34] and an associated progressive decline in GFR can
occur [23, 36]. End-stage renal failure in adults secondary
to ifosfamide has previously been documented in three pa-
tients after cumulative ifosfamide doses of 56g/m2,8 0g / m 2
and 33g/m2 [15]. All of these patients had been pretreated
with cisplatin, whereas only one of the cases we report had
previously received this agent.
Hypophosphatemic rickets occurs in 5–18% [17, 23, 24]
of children treated with ifosfamide and may be the ﬁrst man-
ifestation of the underlying renal abnormalities [23, 24].
There are only four published cases of adults with Fanconi
syndrome and renal osteomalacia secondary to ifosfamide
[37–40]. In three of these, patients have displayed associated
symptoms of signiﬁcant renal dysfunction such as polyuria
and polydipsia. By contrast, our patients were clinically wellD. N. Church et al. 5
at the time of diagnosis of stress fractures, leading to the sus-
picion of bone metastases.
Our experience highlights the fact that tubular and skele-
tal complications of ifosfamide are not restricted exclusively
to a high-risk paediatric population. Indeed our second case
occurred in a patient without any risk factors receiving stan-
dard drug doses. These ﬁndings clearly have implications for
patient monitoring during and after ifosfamide chemother-
apy. Whilst a comprehensive assessment of kidney func-
tion as described in the paediatric literature [41]m a yn o t
be appropriate for all adult patients, assessment of GFR by
51Cr-EDTA clearance [42] and tubular function by serum
andurineelectrolytemeasurements(includingcalculationof
the renal tubular threshold for phosphate) [41] is straight-
forward and may help prevent the complications we de-
scribe. Unfortunately, the paucity of data on this subject in
adults means that when faced with subtle changes in tubu-
lar function, clinicians may not have the evidence available
upon which to base decisions as how to adjust ifosfamide
doses.
These cases demonstrate the need for clinicians to be vig-
ilant for signs of renal tubular dysfunction in patients receiv-
ing ifosfamide, particularly if cisplatin is pretreated, as timely
intervention may prevent skeletal complications of this drug.
They also illustrate the point that when faced with a pa-
tient in the clinic with bone pain and abnormal isotope bone
scan after ifosfamide treatment, oncologists should be mind-
ful that the cause may in fact be insuﬃciency fractures sec-
ondary to osteomalacia rather than metastatic disease, and
futher skeletal imaging may be required to diﬀerentiate be-
tween the two. This clinical caveat may be of increasing rele-
vance,asarecentstudyhasdocumentedhypophosphataemia
and abnormal bone metabolism in patients treated with the
tyrosine kinase inhibitor imatinib, likely through inhibition
of the platelet-derived growth factor (PDGF) receptor [43].
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